Blog Posts

Sanofi and Novartis Fight HRSA’s 340B Contract Pharmacy Demand Letters

Sanofi yesterday sent HRSA a long letter defending its limits on 340B contract pharmacy. | Shutterstock
Drug manufacturer Sanofi yesterday sent the U.S. Health Resources and Services Administration (HRSA) a 30-page defense of its requirement that 340B covered entities must submit their contract pharmacy claims data to a vendor to continue to be able to access
Read More »

340B Hospitals Ask Supreme Court Again to End Steep Medicare Drug Payment Cut

Hospital groups have urged the U.S. Supreme Court again to set aside a deep cut in Medicare Part B drug reimbursement for 340B purchased drugs. | Shutterstock
National hospital groups urged the U.S. Supreme Court last Friday to review and reverse a federal appellate decision upholding a steep cut in hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

Please Login or Become a

Read More »

Brooks-LaSure Sworn in as CMS Administrator

HHS Secretary Xavier Becerra (left) administers the oath of office to new CMS Administrator Chiquita Brooks-LaSure as her husband, Allyn Brooks-LaSure looks on.
Chiquita Brooks-LaSure last Thursday was formally sworn in as Administrator of the Centers for Medicare and Medicaid Services (CMS), setting in place another key Biden administration official with influence on the 340B program.

Please Login or

Read More »

Grassroots Group Launches Regional Events to Promote 340B’s Importance

Community Voices for 340B (CV340B) promotes awareness of the 340B program through in-person seminars and webinars.
Community Voices for 340B (CV340B), the first non-profit grassroots organization focused on promoting the importance of the 340B program, kicked off the first of series of regional educational webinars scheduled last week. The event, which was focused on the Northeast
Read More »

BREAKING: Novartis Sues HRSA in Defense of its 340B Contract Pharmacy Policy

Novartis sued HRSA yesterday to stop it from enforcing its interpretation of the 340B statute's contract pharmacy requirements, and from imposing civil monetary penalties against Novartis for alleged violations. | Shutterstock
Novartis Pharmaceuticals has sued the U.S. Health Resources and Services Administration (HRSA) over the agency’s May 17 letter telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies are illegal.

Please

Read More »

HHS Wants to Audit 340B Providers to See How They Use 340B Net Income

HRSA, headquartered in this suburban Washington office building, would be empowered to audit 340B covered entities to see how they use income from 340B drug purchases, under a Biden administration proposal issued today.
The Biden administration this afternoon proposed amending the 340B statute to let federal health officials audit 340B covered entities “to determine how net income from purchases under [340B] are used by the covered entity.”

Please Login

Read More »

Late Breaking Developments in Lilly and AstraZeneca’s 340B Contract Pharmacy Lawsuits

A federal district judge in Indianapolis late this afternoon declined to temporarily restrain federal health officials from requiring drug maker Eli Lilly, based on a May 17 enforcement letter, to provide 340B discounts on drugs dispensed by contract pharmacies. | Shutterstock
A federal district judge in Indianapolis late this afternoon declined to temporarily restrain federal health officials from requiring drug maker Eli Lilly, based on a May 17 enforcement letter, to provide 340B discounts on drugs dispensed by contract pharmacies.
Read More »

As June 1 Deadline Looms, Drug Manufacturers and Feds Make Their Case in New Jersey Federal Court

Drug makers Novo Nordisk and Sanofi and the federal government filed briefs Tuesday and Wednesday in federal district court in New Jersey in the two manufacturers’ separate challenges to the contract pharmacy requirements.
Drug makers Novo Nordisk and Sanofi and the federal government filed briefs Tuesday and Wednesday in federal district court in New Jersey in those two manufacturers’ separate challenges to the contract pharmacy requirements.

Please Login or

Read More »